HIV-HCV co-infection facing HCV protease inhibitor licensing: Implications for clinicians

Liver International

Volumn 32, Issue 8, 2012, Pages 1194-1199

  Ingiliz, Patrick ^a   Rockstroh, Jürgen K ^b  

^a Medical Center for Infectious Diseases Berlin   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Boceprevir; DAA; HIV HCV co infection; Liver fibrosis; Telaprevir

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; BOCEPREVIR; CYTOCHROME P450 3A4; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FOSAMPRENAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LAMIVUDINE; LOPINAVIR; MARAVIROC; METHADONE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NONSTRUCTURAL PROTEIN 3; PEGINTERFERON; PEGINTERFERON ALPHA2A; RALTEGRAVIR; RIBAVIRIN; RIFABUTIN; RIFAMPICIN; RITONAVIR; SILDENAFIL; STAVUDINE; TELAPREVIR; TENOFOVIR; ZIDOVUDINE;

ANEMIA; BILIRUBIN BLOOD LEVEL; CHOLELITHIASIS; COLLAPSE; DECOMPENSATED LIVER CIRRHOSIS; DECREASED APPETITE; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; DRUG TREATMENT FAILURE; DYSGEUSIA; ERECTILE DYSFUNCTION; FATIGUE; FEVER; GENOTYPE; HEADACHE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPOTENSION; JAUNDICE; LACTIC ACIDOSIS; LICENSING; LIVER DISEASE; LIVER FIBROSIS; LOW DRUG DOSE; MIXED INFECTION; NAUSEA; NEUTROPENIA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICIAN; PRURITUS; RASH; REVIEW; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; VOMITING; WEIGHT REDUCTION;

COINFECTION; DRUG INTERACTIONS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; OLIGOPEPTIDES; PROLINE; SERINE PROTEINASE INHIBITORS;

EID: 84865155522     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2012.02796.x     Document Type: Review

References (42)

1. Poordad F, McCone J, Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
2. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
3. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
4. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
5. Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P. Viral hepatitis and HIV co-infection. Antiviral Res 2010; 85: 303-15.
6. Danta M, Brown D, Bhagani S, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007; 21: 983-91.
7. Low E, Vogel M, Rockstroh J, Nelson M. Acute hepatitis C in HIV-positive individuals. AIDS Rev 2008; 10: 245-53.
8. Vogel M, Deterding K, Wiegand J, et al. Initial presentation of acute hepatitis C virus (HCV) infection among HIV-negative and HIV-positive individuals-experience from 2 large German networks on the study of acute HCV infection. Clin Infect Dis 2009; 49: 317-9; author reply 9.
9. Rosenthal E, Pialoux G, Bernard N, et al. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepatitis 2007; 14: 183-8.
10. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50: 1387-96.
11. Nunez M, Miralles C, Berdun MA, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007; 23: 972-82.
12. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21: 1073-89.
13. Rallon NI, Soriano V, Naggie S, et al. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. AIDS 2011; 25: 1025-33.
14. Poynard T, Mathurin P, Lai CL, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003; 38: 257-65.
15. Martin P, Di Bisceglie AM, Kassianides C, Lisker-Melman M, Hoofnagle JH. Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection. Gastroenterology 1989; 97: 1559-61.
16. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284: 450-6.
17. Thomas DL, Shih JW, Alter HJ, et al. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 1996; 174: 690-5.
18. Darby SC, Ewart DW, Giangrande PL, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet 1997; 350: 1425-31.
19. Sterling RK, Wegelin JA, Smith PG, et al. Similar progression of fibrosis between HIV/HCV-infected and HCV-infected patients: analysis of paired liver biopsy samples. Clin Gastroenterol Hepatol 2010; 8: 1070-6.
20. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138: 447-62.
21. Butt AA, Kanwal F. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Clin Infect Dis 2012; 54: 96-104.
22. Kempf DJ, Klein C, Chen HJ, et al. Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir. Antivir Chem Chemother 2007; 18: 163-7.
23. van Heeswijk R VA, Boogaerts G, et al. Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers. In: 18th Conference on Retroviruses and Opportunistic Infections, February 27-March 2, Boston, MA, USA, 2011; (Abstract 119).
24. ® (Telaprevir) US Prescribing Information, FDA. 2011. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201917lbl.pdf. Accessed: 24 March 2012, Updated: May 2011.
25. van Heeswijk R GV, Boogaerts G, et al. The pharmocokinetic interaction between telaprevir and raltegravir in healthy volunteers. In: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, Chicago, IL, USA, 2011; (LB A1-1738).
26. Kasserra C, Hughes E, Treitel M, Gupta S, O'Mara E. Clinical pharmacology of BOC: metabolism, excretion, and drug-drug interactions. In: 18th Conference on Retroviruses and Opportunistic Infections, February 27-March 2, Boston, MA, USA, 2011; (Abstract 118).
27. Hulskotte E, Feng HP, Xuan F, et al. Pharmacokinetic interaction between the HCV protease inhibitor Boceprevir and Ritonavir boosted HIV-1 Protease inhibitors Atazanavir, Lopinavir, and Darunavir. In: 19th Conference on Retroviruses and Opportunistic Infections, March 5 to 8, Seattle, WA, USA, 2012; (Paper # 771LB).
28. De Kanter C, Blonk M, Colbers A, et al. The Influence of the HCV Protease Inhibitor Boceprevir on the Pharmacokinetics of the HIV Integrase Inhibitor Raltegravir. In: 19th Conference on Retroviruses and Opportunistic Infections, March 5 to 8, Seattle, WA, USA, 2012; (Paper # 772LB).
29. ® (Boceprevir) US Prescribing Information, FDA. 2011. Available at http://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf Accessed 08 February 2011, Updated: May 2011.
30. van Heeswijk R, Vandevoorde A, Verboven P, et al. The pharmacokinetic interaction between methadone and the investigational HCV protease inhibitor telaprevir. In:46th Annual Meeting of the European Association for the Study of the Liver 2011, March 31-April 3Berlin, Germany, 2011;(Abstract 654).
31. Sulkowski M, Dieterich D, Sherman Ket al. Interim analysis of a phase 2a double-blind study of TVR in combination with pegIFN-alfa2a and RBV in HIV/HCV Co-infected patients. In:18th Conference on Retroviruses and Opportunistic Infections, February 27-March 2, Boston, MA, USA, 2011;(Abstract LB 146).
32. Dieterich D, Soriano V, Sherman K, et al. Telaprevir in Combination with Pegylated Interferon-alfa-2a+RBV in HCV/HIV-co-infected Patients: A 24-Week Treatment Interim Analysis. In: Conference on Retroviruses and Opportunistic Infections March 5-8, Seattle, WA, USA, 2012 (Paper# 46).
33. Sulkowski M, Pol S, Cooper C et al. Boceprevir plus pegylated interferon plus ribavirin for the treatment of HCV/HIV-coinfected patients: End of Treatment (Week 48) Interim Results. In: Conference on Retroviruses and Opportunistic Infections, March 5-8, Seattle, WA, USA, 2012;(Paper #47).
34. Opravil M, Sasadeusz J, Cooper DA, et al. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr 2008; 47: 36-49.
35. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57.
36. Sanchez-Conde M, Montes-Ramirez ML, Miralles P, et al. Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with non-invasive serum markers. J Viral Hepatitis 2010; 17: 280-6.
37. Cacoub P, Carrat F, Bedossa P, et al. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study-ANRS HC02. J Hepatol 2008; 48: 765-73.
38. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-50.
39. The European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel. Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. AIDS 2011; 25: 399-409.
40. Ingiliz P, Valantin MA, Preziosi P, et al. Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfected patients: a retrospective repeated liver biopsy analysis. J Hepatol 2012; 56: 49-54.
41. Mira JA, Lopez-Cortes LF, Merino D, et al. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients. Antivir Ther 2007; 12: 1225-35.
42. Bani-Sadr F, Carrat F, Pol S, et al. Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. J Acquir Immune Defic Syndr 2005; 40: 47-52.